Karl-Erik Andersson to Prognosis
This is a "connection" page, showing publications Karl-Erik Andersson has written about Prognosis.
Connection Strength
0.271
-
Gedda L, Björkelund H, Lebel L, Asplund A, Dubois L, Wester K, Penagos N, Malmqvist M, Andersson K. Evaluation of real-time immunohistochemistry and interaction map as an alternative objective assessment of HER2 expression in human breast cancer tissue. Appl Immunohistochem Mol Morphol. 2013 Dec; 21(6):497-505.
Score: 0.075
-
Campeau L, Soler R, Andersson KE. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011 Dec; 12(6):396-403.
Score: 0.065
-
Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002 Apr; 19(6):390-6.
Score: 0.034
-
Andersson KE, Chapple CR, Höfner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol. 2002 Apr; 19(6):436-42.
Score: 0.034
-
Kirschner-Hermanns R, Anding R, Rosier P, Birder L, Andersson KE, Djurhuus JC. Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014. Neurourol Urodyn. 2016 Feb; 35(2):318-23.
Score: 0.022
-
Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One. 2016; 11(1):e0145545.
Score: 0.022
-
Peng Z, Andersson K, Lindholm J, Bodin I, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One. 2014; 9(10):e109610.
Score: 0.020